Ranbaxy Launches Generic Cefaclor In UK
Ranbaxy (UK), the local subsidiary of Indian firm Ranbaxy Laboratories,has launched a generic version of Dista's second-generation cephalosporin antibiotic Distaclor (cefaclor) onto the UK market.
Peter Wittner, UK business manager at the company, told the Marketletter that "doctors are now able to prescribe cefaclor 250mg capsules, knowing that a high-quality generic, rather than a parallel import, will fill their prescription." Dista withdrew its 250mg formulation in the middle of 1996 and replaced it with 375mg modified-release tablets. He noted that in some cases, doctors may prefer to use immediate-release 250mg capsules which produce higher plasma levels. The range also includes 500mg capsule and two liquid suspension formulations.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze